US-based medical device company STAAR Surgical has secured approval from the Medical Devices Bureau of Health Canada to distribute EVO Visian ICL, the company’s implantable collamer lens in Canada.

STAAR’s next-generation lens, EVO ICL is implanted in the eye, where it works with the patient’s natural eye to repair their vision.

The EVO ICL, unlike traditional lenses, is placed inside the eye between the iris and the natural lens where it can stay for an indefinite period.

"This represents an important new treatment option for eligible patients between 21 and 45 years old living with nearsightedness."

The lens is made of Staar Surgical’s patented collamer which is a collagen based material, an organic compound which characterises the lens’ ability to work with the natural lens of the eye.

The EVO ICL, with its central hole, allows enhanced refractive outcomes while ensuring efficiency and comfort for both the patient and the surgeon by eliminating the extra surgical step of the peripheral iridotomy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

See Also:

STAAR Surgical president and CEO Caren Mason said: "We are very pleased with Health Canada’s approval that allows us to offer the EVO ICL for myopia, with a broad power range of -3.0 to -18.0 diopters, to our surgeons and their patients in Canada.

"This represents an important new treatment option for eligible patients between 21 and 45 years old living with nearsightedness.

"This approval reinforces our deep commitment to patients seeking visual freedom, as we continue to build our growing EVO ICL portfolio."

The EVO ICL has recently exhibited its functionality at the American Society of Cataract and Refractive Surgery (ASCRS) meeting earlier this month in the US as part of the Evolution of Visual Freedom initiative.

About 200,000 lenses from the EVO ICL genre have been implanted across the world till date.